Skip to search boxSkip to navigationSkip to main content

Confirmation of novel type 1 diabetes risk loci in families

  • J. D. Cooper(corresponding author)
    ,
  • J. M.M. Howson
    ,
  • D. Smyth
    ,
  • N. M. Walker
    ,
  • H. Stevens
    ,
  • J. H.M. Yang
*Corresponding author for this work
  • University of Cambridge
    ,
  • ,
  • Barbara Davis Center for Childhood Diabetes
    ,
  • National Institutes of Health
    ,
  • University of Virginia
    ,
  • Hoffmann-La Roche Inc.
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Aims/hypothesis Over 50 regions of the genome have been associated with type 1 diabetes risk, mainly using large case/control collections. In a recent genome-wide association (GWA) study, 18 novel susceptibility loci were identified and replicated, including replication evidence from 2,319 families. Here, we, the Type 1Diabetes Genetics Consortium(T1DGC), aimed to exclude the possibility that any of the 18 loci were false-positives due to population stratification by significantly increasing the statistical power of our family study. Methods We genotyped the most disease-predicting singlenucleotide polymorphisms at the 18 susceptibility loci in 3,108 families and used existing genotype data for 2,319 families from the original study, providing 7,013 parent-child trios for analysis. We tested for association using the transmission disequilibrium test. Results Seventeen of the 18 susceptibility loci reached nominal levels of significance (p<0.05) in the expanded family collection, with 14q24.1 just falling short (p=0.055). When we allowed for multiple testing, ten of the 17 nominally significant loci reached the required level of significance (p< 2.8×10 -3). All susceptibility loci had consistent direction of effects with the original study. Conclusions/interpretation The results for the novel GWA study-identified loci are genuine and not due to population stratification. The next step, namely correlation of the most disease-associated genotypes with phenotypes, such as RNA and protein expression analyses for the candidate genes within or near each of the susceptibility regions, can now proceed.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 996-1000 (5 pages)

Journal (Volume, Issue Number)

Diabetologia (Volume 55, Issue 4)

Publication milestones

  • Published - 04/2012

Publication status

Published - 04/2012

ISSN

0012-186X

Publication IDs

  • Scopus: 84862832735
  • PubMed: 22278338

Publication metrics

Metrics

Scopus
citations
SciVal
FWCI
1.53
SciVal
Author count
19
SciVal
citations
33
SciVal
Paper percentile
87
Fractional count
1
Fractional count
0.05
Fractional count
18
Fractional count
0.95
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
71
Citation count
50

Funding Details

Acknowledgements We gratefully acknowledge the participation of all the patients and family members. We acknowledge use of DNA from the Human Biological Data Interchange and Diabetes UK for the USA and UK multiplex families, respectively, D. Savage of the Belfast Health and Social Care Trust, C. Patterson and D. Carson of Queen\u2019s University Belfast and P. Maxwell of Belfast City Hospital for the Northern Irish families, the Genetics of Type 1 Diabetes in Finland (GET1FIN; J. Tuomilehto, L. Kinnunen, E. Tuomilehto-Wolf, V. Harjutsalo and T. Valle of the National Public Health Institute, Helsinki) for the Finnish families, and C. Guja and C. Ionescu-Tirgoviste of the Institute of Diabetes \u2018N Paulescu\u2019, Romania for the Romanian families. This research uses resources provided by the T1DGC, a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases, National Human Genome Research Institute, National Institute of Child Health and Human Development, and Juvenile Diabetes Research Foundation International (JDRF) and supported by U01 DK062418. We also thank H. Stevens, P. Clarke, G. Coleman, S. Duley, D. Harrison, S. Hawkins, M. Maisuria, T. Mistry and N. Taylor from the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory for preparation of DNA samples and David Clayton from the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory for useful discussions. Funding This work was funded by the Juvenile Diabetes Research Foundation International, the Wellcome Trust and the National Institute for Health Research Cambridge Biomedical Centre. The Cambridge Institute for Medical Research is in receipt of a Wellcome Trust Strategic Award (079895).
FundersFunding numbers
NICHD
-
NHGRI
-
NIAID
-
NIHR Cambridge Biomedical Research Centre
-
JDRF
U01 DK062418
NIDDK
R01DK046635
-
079895